NCT03142321View on ClinicalTrials.gov

Defining Predictors of RT Response to Vedolizumab in IBD

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

May 22, 2024

Study Completion Date

October 28, 2024

Conditions
Crohn Disease of Small Intestine
Interventions
DRUG

Vedolizumab 300 MG Injection [Entyvio]

Vedolizumab Injection

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT03142321 - Defining Predictors of RT Response to Vedolizumab in IBD | Biotech Hunter | Biotech Hunter